{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:55:09Z","timestamp":1772283309534,"version":"3.50.1"},"reference-count":22,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2704204"],"award-info":[{"award-number":["2022YFC2704204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Background: Malignant gliomas remain largely refractory to current therapies, in part because abnormal tumor vasculature and a disrupted blood-brain barrier limit intratumoral drug delivery and cause severe tumor-associated edema. The oncolytic adenovirus KD01 is a conditionally replicating adenovirus type 5 with a 27-bp deletion in Early Region 1A (E1A) and a truncated BH3-Interacting Domain Death Agonist (tBID) expression cassette inserted into the E3 region. This study investigated whether bevacizumab-induced vascular normalization would enhance the delivery and efficacy of KD01 in gliomas. Methods: The oncolytic activity and mitochondrial effects of KD01 were evaluated in human glioma cell lines using cell viability assays, JC-1 staining, quantitative real-time-polymerase chain reaction (qRT-PCR), and western blotting for BID\/tBID. An orthotopic LN229 nude mouse model was used to assess a sequential bevacizumab\u2192KD01 regimen. Mice were randomized to receive PBS, bevacizumab, KD01, or combination treatment. Body weight and survival were recorded. Tumor cell proliferation (Ki-67), tumor vasculature (CD31), brain water content (\u0394Water%), serum biochemistry, coagulation parameters, and organ weights were analyzed to evaluate antitumor activity, edema, and systemic safety. Results: KD01 induced robust dose- and time-dependent cytotoxicity in glioma cells and caused marked mitochondrial depolarization, accompanied by increased BID mRNA expression, loss of full-length BID, and accumulation of tBID. In the orthotopic LN229 model, bevacizumab administered 48 h before KD01 significantly improved overall outcomes compared with either monotherapy. The bevacizumab\u2192KD01 group showed improved preservation of body weight, pronounced prolongation of survival, and the lowest Ki-67 labeling index. This group also exhibited reduced brain water content (\u0394Water%), consistent with sparser CD31-positive vessels resulting from vascular normalization and oncolysis, indicating effective attenuation of tumor-associated edema. Serum liver and kidney function tests, platelet counts, coagulation indices, and major organ weights were comparable across treatment groups, suggesting no additional systemic toxicity associated with combination treatment. Conclusions: KD01 exerts potent tBID-mediated mitochondrial oncolytic activity against glioma cells. When used as a priming strategy, transient vascular normalization induced by bevacizumab enhanced the intratumoral efficacy of KD01 in an orthotopic glioma model while maintaining a favorable safety profile. These findings support a simple, sequence-dependent combination approach integrating anti-VEGF therapy with oncolytic virotherapy for the treatment of malignant gliomas.<\/jats:p>","DOI":"10.31083\/fbl48473","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:56:49Z","timestamp":1772279809000},"source":"Crossref","is-referenced-by-count":0,"title":["Bevacizumab-Primed Vascular Normalization Enhances Intratumoral Delivery and Efficacy of the tBID-Armed Oncolytic Adenovirus KD01 in Glioma"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9930-0997","authenticated-orcid":true,"given":"Wei","family":"Gong","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, 430030 Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6098-3050","authenticated-orcid":true,"given":"Baiwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, 430030 Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4826-4091","authenticated-orcid":true,"given":"Zuodong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, 430030 Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8463-7460","authenticated-orcid":true,"given":"Chansachak","family":"Chea","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, 430030 Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5747-2096","authenticated-orcid":true,"given":"Fei","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Tongji Hospital, Tongji Medical School, Huazhong University of Sciences and Technology, 430030 Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"16242","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Song KW, Lim M, Monje M. Complex neural-immune interactions shape glioma immunotherapy. Immunity. 2025; 58: 1140\u20131160.","DOI":"10.1016\/j.immuni.2025.04.017"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Wang W, Li T, Cheng Y, Li F, Qi S, Mao M, et al. Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization. Cancer Cell. 2024; 42: 815\u2013832.e12.","DOI":"10.1016\/j.ccell.2024.03.013"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Tsien CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, et al. NRG Oncology\/RTOG1205: A Randomized Phase II Trial of Concurrent Bevacizumab and Reirradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2023; 41: 1285\u20131295.","DOI":"10.1200\/JCO.22.00164"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhang M, Zhu J, Bao Y, Ao Q, Mao X, Qiu Z, et al. Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies. Frontiers in Bioengineering and Biotechnology. 2025; 13: 1589841.","DOI":"10.3389\/fbioe.2025.1589841"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Li B, Xu D, Zhou J, Wang SC, Cai YX, Li H, et al. Monitoring Bevacizumab-Induced Tumor Vascular Normalization by Intravoxel Incoherent Motion Diffusion-Weighted MRI. Journal of Magnetic Resonance Imaging: JMRI. 2022; 56: 427\u2013439.","DOI":"10.1002\/jmri.28012"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025; 188: 1119\u20131136.e23.","DOI":"10.1016\/j.cell.2024.12.010"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Long L, Gao J, Zhang R. PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression. Viruses. 2023; 15: 1153.","DOI":"10.3390\/v15051153"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Guo J, Xiong S, Zhang X, Gong W, Si Y, Ma D, et al. Preclinical Efficacy and Safety of an Oncolytic Adenovirus KD01 for the Treatment of Bladder Cancer. Pharmaceuticals (Basel, Switzerland). 2025; 18: 511.","DOI":"10.3390\/ph18040511"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ren F, Narita R, Rashidi AS, Fruhw\u00fcrth S, Gao Z, Bak RO, et al. ER stress induces caspase-2-tBID-GSDME-dependent cell death in neurons lytically infected with herpes simplex virus type 2. The EMBO Journal. 2023; 42: e113118.","DOI":"10.15252\/embj.2022113118"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Dai Z, Si Y, Xiong S, Li Y, Ye J, Gao Q, et al. Chimeric Ad5\/35 oncolytic adenovirus overcome preexisting neutralizing antibodies and enhance tumor targeting efficiency. Cancer Gene Therapy. 2025; 32: 418\u2013436.","DOI":"10.1038\/s41417-025-00884-x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Xie Y, Yang F, He L, Huang H, Chao M, Cao H, et al. Single-cell dissection of the human blood-brain barrier and glioma blood-tumor barrier. Neuron. 2024; 112: 3089\u20133105.e7.","DOI":"10.1016\/j.neuron.2024.07.026"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Kurdi M, Bamaga A, Alkhotani A, Alsharif T, Abdel-Hamid GA, Selim ME, et al. Mitochondrial DNA Alterations in Glioblastoma and Current Therapeutic Targets. Frontiers in Bioscience (Landmark Edition). 2024; 29: 367.","DOI":"10.31083\/j.fbl2910367"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Cerretti G, Bosio A, Librizzi G, Pintacuda G, Caccese M, Salvalaggio A, et al. Bevacizumab in recurrent glioblastoma: does dose matter? Our monocentric and comparative experience. Journal of Neuro-oncology. 2025; 173: 449\u2013456.","DOI":"10.1007\/s11060-025-04992-4"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Beylerli O, Gareev I, Kaprin A, Ahmad A, Chekhonin V, Yang S, et al. Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma. Cancer Gene Therapy. 2025; 32: 762\u2013777.","DOI":"10.1038\/s41417-025-00914-8"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Nowacka A, \u015aniegocki M, Smuczy\u0144ski W, Bo\u017ci\u0142ow D, Zi\u00f3\u0142kowska E. Angiogenesis in Glioblastoma-Treatment Approaches. Cells. 2025; 14: 407.","DOI":"10.3390\/cells14060407"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ma R, Li Z, Chiocca EA, Caligiuri MA, Yu J. The emerging field of oncolytic virus-based cancer immunotherapy. Trends in Cancer. 2023; 9: 122\u2013139.","DOI":"10.1016\/j.trecan.2022.10.003"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"He T, Hao Z, Lin M, Xin Z, Chen Y, Ouyang W, et al. Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation. Oncoimmunology. 2022; 11: 2093054.","DOI":"10.1080\/2162402X.2022.2093054"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Wang M, Chen Y, Tian L, Wu C, Chen J, Hu J, et al. Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. Cancer Discovery. 2025; 15: 1883\u20131904.","DOI":"10.1158\/2159-8290.CD-24-1033"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity. Cell. 2020; 180: 188\u2013204.e22.","DOI":"10.1016\/j.cell.2019.11.036"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Swamy K. Vascular normalization and immunotherapy: Spawning a virtuous cycle. Frontiers in Oncology. 2022; 12: 1002957.","DOI":"10.3389\/fonc.2022.1002957"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, et al. Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis. Cancer Immunology, Immunotherapy: CII. 2024; 73: 193.","DOI":"10.1007\/s00262-024-03774-7"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Chen Y, Chen X, Bao W, Liu G, Wei W, Ping Y. An oncolytic virus-T cell chimera for cancer immunotherapy. Nature Biotechnology. 2024; 42: 1876\u20131887.","DOI":"10.1038\/s41587-023-02118-7"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/2\/10.31083\/FBL48473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T11:56:52Z","timestamp":1772279812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/2\/10.31083\/FBL48473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02012-5"],"URL":"https:\/\/doi.org\/10.31083\/fbl48473","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"48473"}}